Compare Novavax Inc (NVAX) vs Consumer Staples Select Sector SPDR Fund (XLP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Consumer Staples Select Sector SPDR Fund — how do they compare? Novavax Inc trades at $7.96 (market cap $1.31B), while Consumer Staples Select Sector SPDR Fund trades at $85.08. The key difference: Consumer Staples Select Sector SPDR Fund is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.
| NVAX | XLP | |
|---|---|---|
Market Cap | $1.31B | — |
Sector | Health | — |
52-Week High | $11.19 | $90.00 |
52-Week Low | $6.22 | $75.61 |
Enterprise Value | $889.30M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVAX trades at $7.95, up 0.76% on the day, with a bullish technical signal despite mixed indicators. The company reported a net income of $440.30M for 2025, a significant turnaround from prior losses, and has beaten earnings estimates for three consecutive quarters. Recent news highlights Q2 2026 results and a raised revenue outlook, driven by licensing milestones with Sanofi.
The outlook is cautiously optimistic given strong analyst buy ratings (73.92%) and improved financials, but risks include persistent negative cash flows, high debt, and competitive vaccine market pressures. Investment appeal hinges on execution of partnerships and cost management to sustain profitability.
XLP trades at $85.08 with minimal daily movement (+0.15%), reflecting stable defensive positioning. Technical indicators show mixed signals with a neutral overall rating, while analyst consensus remains strongly bullish with 100% buy ratings. The consumer staples ETF benefits from recent positive sector momentum and defensive characteristics during market uncertainty.
The outlook remains positive given the defensive nature of consumer staples amid economic uncertainty, with potential for steady dividend income. Key risks include sector rotation away from defensive plays and valuation concerns if growth expectations moderate. The 2.6% dividend yield provides income support while awaiting capital appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Consumer Staples Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Consumer Staples companies by the GICS®. It is non-diversified.
Read more on XLP →
